None

Vismodegib (Vismodegib) is the first Hedgehog (Hh) pathway inhibitor approved in the United States for the treatment of adults with metastatic or locally advanced basal cell carcinoma (BCC). It was approved by the U.S. FDA on January 30, 2012, and by the European Commission on July 12, 2013, for the treatment of adult patients with symptomatic metastatic basal cell carcinoma or locally advanced basal cell carcinoma that is not suitable for surgery or radiation therapy. Vimodegib selectively inhibits the Hh signaling pathway, binding to and inhibiting Smoothened (SMO), a key signal transduction component of this pathway. Vismodegib was discovered by Genentech under a collaboration agreement with Curis.

Experience in target-based drug discovery shows that vismodegib targets theHh pathway to block abnormal signaling caused by mutational inactivation of the negative regulator PTCH1 or activation of SMO mutations. Due to the importance of the Hedgehog pathway in embryogenesis and organ development, vismodegib is contraindicated in pregnancy. Vimodegib has been shown to be teratogenic in studies in rats, causing craniofacial malformations, perineal patency, normal growth retardation, and missing or fused digits. Patients of childbearing potential should be advised to use effective contraception while using this product.

The original drug of Vimodegib is not currently on the market in the country, so it cannot be included in medical insurance. Overseas, Vimodegiboriginal drug has Turkish version and European version, specificationsThe price of 150mg*28 capsules per box may be around RMB 10,000-30,000 (the price may fluctuate due to the exchange rate). The price is very expensive, and there are currently no generic versions of Vimodegib. For more drug information and specific prices, please consult Yaodei Medical Consultants.